Olshove Vincent, Berndsen Nicole, Sivarajan Veena, Nawathe Pooja, Phillips Alistair
1 Congenital Heart Program, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2 Critical Care Medicine, Congenital Cardiac Intensive Care Unit, Depart-ment of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Perfusion. 2018 Apr;33(3):194-202. doi: 10.1177/0267659117733810. Epub 2017 Oct 6.
Cardiac surgery on Jehovah's Witnesses (JW) can be challenging, given the desire to avoid blood products. Establishment of a blood conservation program involving the pre-, intra- and post-operative stages for all patients may lead to a minimized need for blood transfusion in all patients.
Pre-operatively, all JW patients were treated with high dose erythropoietin 500 IU/kg twice a week. JW patients were compared to matching non-JW patients from the congenital cardiac database, two per JW to serve as control. Blood use, ventilation time, bypass time, pre-operative hematocrit, first in intensive care unit (ICU) and at discharge and 24 hour chest drainage were compared. Pre-operative huddle, operating room huddle and post-operative bedside handoff were done with the congenital cardiac surgeon, perfusionist, anesthesiologist and intensive care team in all patients for goal alignment.
Five JW patients (mean weight 24.4 ± 25.0 Kg, range 6.3 - 60 Kg) were compared to 10 non-JW patients (weight 22.0 ± 22.8 Kg, range 6.2 - 67.8 Kg). There was no difference in bypass, cross-clamp, time to extubation (0.8 vs. 2.1 hours), peak inotrope score (2.0 vs. 2.3) or chest drainage. No JW patient received a blood product compared to 40% of non-JW. The pre-operative hematocrit (Hct) was statistically greater for the JW patients (46.1 ± 3.3% vs. 36.3 ± 4.7%, p<0.001) and both ICU and discharge Hct were higher for the JW (37 ± 1.8% vs 32.4 ± 8.0% and 41 ± 8.1% vs 34.8 ± 7.9%), but did not reach statistical significance. All patients had similar blood draws during the hospitalization (JW x 18 mL/admission vs non-JW 20 mL/admission).
The continuous application and development of blood conservation techniques across the continuum of care allowed bloodless surgery for JW and non-JW patients alike. Blood conservation is a team sport and to make significant strides requires participation and input by all care providers.
鉴于耶和华见证人(JW)患者希望避免使用血制品,对他们进行心脏手术具有挑战性。为所有患者制定一个涵盖术前、术中和术后阶段的血液保护计划,可能会使所有患者对输血的需求降至最低。
术前,所有JW患者每周两次接受500 IU/kg的高剂量促红细胞生成素治疗。将JW患者与先天性心脏病数据库中匹配的非JW患者进行比较,每2名JW患者匹配2名非JW患者作为对照。比较了血液使用情况、通气时间、体外循环时间、术前血细胞比容、入住重症监护病房(ICU)时及出院时的情况以及24小时胸腔引流量。所有患者均由先天性心脏病外科医生、灌注师、麻醉师和重症监护团队进行术前碰头会、手术室碰头会和术后床边交接,以达成目标一致。
5名JW患者(平均体重24.4±25.0 Kg,范围6.3 - 60 Kg)与10名非JW患者(体重22.0±22.8 Kg,范围6.2 - 67.8 Kg)进行了比较。体外循环、主动脉阻断、拔管时间(0.8小时对2.1小时)、最大血管活性药物评分(2.0对2.3)或胸腔引流量方面无差异。与40%的非JW患者相比,没有JW患者接受血制品。JW患者的术前血细胞比容(Hct)在统计学上更高(46.1±3.3%对36.3±4.7%,p<0.001),JW患者在ICU及出院时的Hct也更高(37±1.8%对32.4±8.0%以及41±8.1%对34.8±7.9%),但未达到统计学显著性。所有患者在住院期间的抽血量相似(JW患者每次入院18 mL对非JW患者20 mL)。
在整个护理过程中持续应用和发展血液保护技术,使JW和非JW患者都能实现无血手术。血液保护是一项团队工作,要取得重大进展需要所有护理人员的参与和投入。